Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Oct 25:11:788210.
doi: 10.3389/fonc.2021.788210. eCollection 2021.

Editorial: Nanomedicine in Cancer Targeting and Therapy

João Paulo Figueiró Longo  1 , Luis Alexandre Muehlmann  2 , Marcelo Calderón  3   4 , Christian Stockmann  5 , Ricardo Bentes Azevedo  1
Affiliations
Editorial

Editorial: Nanomedicine in Cancer Targeting and Therapy

João Paulo Figueiró Longo et al. Front Oncol. .
No abstract available

Keywords: immunology; innovation; nanomedicine; nanotecehnology; oncology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Nanomedicine milestones.
See this image and copyright information in PMC

Comment on

  • Editorial on the Research Topic Nanomedicine in Cancer Targeting and Therapy

References

    1. Lammers T, Ferrari M. The Success of Nanomedicine. Nano Today (2020) 31:100853–4. doi: 10.1016/j.nantod.2020.100853 - DOI - PMC - PubMed
    1. Figueiró Longo JP, Muehlmann LA. Nanomedicine Beyond Tumor Passive Targeting: What Next? Nanomedicine (2020) 15:19. doi: 10.2217/nnm-2020-0208 - DOI - PubMed
    1. Metselaar JM, Lammers T. Challenges in Nanomedicine Clinical Translation. Drug delivery Trans Res (2020) 10:3. doi: 10.1007/s13346-020-00740-5 - DOI - PMC - PubMed
    1. Figueiró Longo JP, Muehlmann LA. How has Nanomedical Innovation Contributed to the COVID-19 Vaccine Development? Nanomedicine (2021) 16:14. doi: 10.2217/nnm-2021-0035 - DOI - PMC - PubMed
    1. Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. . Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med (2018) 379:1. doi: 10.1056/NEJMoa1716153 - DOI - PubMed

Publication types

LinkOut - more resources